MBIP

MBIP is a dual-function protein that operates both as a structural component of the metazoan ATAC histone acetyltransferase complex and as a regulator of stress-activated MAP kinase signaling (PMID:18838386, PMID:22345504). It was first defined biochemically through its direct physical interaction with the leucine-zipper-like motif of the MAP3K MUK/DLK/ZPK (MAP3K12), where binding inhibits MAP3K12-driven JNK/SAPK activation in a kinase-specific manner (PMID:10801814). MBIP is a stable subunit of the human ATAC complex assembled around the GCN5/PCAF acetyltransferases, ADA2-A, ADA3, WDR5, and additional histone-fold subunits that engage TBP, and its N-terminal region is derived from the MoaE molybdopterin synthase subunit but has lost catalytic residues, repurposing this fold as a non-catalytic MAPK-regulatory module within ATAC (PMID:18838386, PMID:22345504). In cancer, MBIP acts as a pro-metastatic effector: in non-small-cell lung carcinoma it activates the JNK pathway and induces matrix metalloproteinase expression to drive proliferation, migration, invasion, and metastasis (PMID:32963352), and in esophageal squamous cell carcinoma it promotes JNK and p38 phosphorylation to trigger epithelial-mesenchymal transition and metastasis (PMID:38199596). Beyond these MAPK-linked roles and its ATAC membership, the biochemical mechanism by which MBIP integrates chromatin acetylation and kinase regulation has not been resolved in the available corpus.

1. 2000 Medium

   Established MBIP's founding molecular activity by showing it directly binds a specific MAP3K and selectively dampens stress-induced JNK signaling, defining it as a kinase-binding inhibitory protein rather than a general signaling modulator.

   Evidence Co-immunoprecipitation and JNK/SAPK kinase activity assays in 293T cells with COT/Tpl-2 specificity control

   PMID:10801814

   Open questions at the time

   • Inhibition was only partial and tested by overexpression, not endogenous loss-of-function
   • No structural basis for leucine-zipper binding determined
   • Did not connect MBIP to any chromatin role
2. 2008 High

   Reframed MBIP as a bona fide subunit of the ATAC histone acetyltransferase complex, revealing a chromatin-associated context independent of its prior MAPK role.

   Evidence Biochemical purification of human ATAC followed by mass spectrometry subunit identification and TBP interaction characterization

   PMID:18838386

   Open questions at the time

   • Did not define MBIP's specific contribution to ATAC acetyltransferase activity or assembly
   • Relationship between ATAC membership and MAP3K12 inhibition left unaddressed
3. 2012 Medium

   Reconciled the two functions by mapping the MAPK-regulatory determinants to MBIP's MoaE-derived N-terminal region and showing the fold is catalytically dead, establishing a non-catalytic, repurposed domain within ATAC.

   Evidence Drosophila ortholog (CG10238/dMoaE) interaction assays, ATAC proteomics, and mutagenesis-based domain mapping with cross-metazoan sequence analysis

   PMID:22345504

   Open questions at the time

   • Mechanistic link between the MoaE-derived domain and JNK inhibition not biochemically resolved
   • Based on Drosophila ortholog
   • How ATAC incorporation gates MAPK regulation unknown
4. 2018 Low

   Implicated MBIP in regulating expression of the neighboring gene NKX2-1, raising a possible chromatin/regulatory role in disease, though through indirect genetic evidence.

   Evidence Array CGH deletion mapping and transcript quantification in fibroblasts from a single benign hereditary chorea family

   PMID:29621620

   Open questions at the time

   • Single family with indirect transcript-level evidence only
   • Causality between MBIP deletion and NKX2-1 reduction not mechanistically established
   • Possible positional/regulatory artifact not excluded
5. 2020 Medium

   Inverted the original inhibitory model in a disease context by showing MBIP drives, rather than suppresses, JNK signaling to promote an invasive MMP-dependent metastatic phenotype in lung cancer.

   Evidence Gain- and loss-of-function in NSCLC lines, in vivo metastasis assays, JNK and MMP readouts with rescue

   PMID:32963352

   Open questions at the time

   • Molecular basis for activating rather than inhibiting JNK not defined
   • Role of ATAC membership in this phenotype untested
   • Single cancer-type, single lab
6. 2024 Medium

   Extended the pro-metastatic MAPK role to a second tumor type, showing MBIP activates both JNK and p38 to drive EMT, reinforcing a context-dependent activating function.

   Evidence RNA-seq, western blotting, Transwell assays, mouse xenografts, and pathway-inhibitor rescue in ESCC

   PMID:38199596

   Open questions at the time

   • Direct biochemical mechanism of JNK/p38 activation not shown
   • Does not reconcile activating versus inhibitory effects on the same pathway
   • Contribution of ATAC acetyltransferase activity not separated from MAPK effects

• It remains unresolved how MBIP's MoaE-derived non-catalytic domain mechanistically toggles between inhibiting and activating stress MAPK signaling, and how this is coupled to its function within the ATAC histone acetyltransferase complex.
• No structural or biochemical model explains the inhibitory-to-activating switch across cell contexts
• The functional interplay between ATAC membership and MAP3K binding is uncharacterized
• No defined substrate or chromatin target attributable specifically to MBIP